Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel
Roque DM, Buza N, Glasgow M, Bellone S, Bortolomai I, Gasparrini S, Cocco E, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Schwartz PE, Santin AD. Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. Clinical & Experimental Metastasis 2013, 31: 101-110. PMID: 24005572, PMCID: PMC3947146, DOI: 10.1007/s10585-013-9614-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarboplatinCystadenocarcinoma, SerousDrug Resistance, NeoplasmFemaleHumansImmunohistochemistryNeoadjuvant TherapyOvarian NeoplasmsPaclitaxelPrognosisReal-Time Polymerase Chain ReactionTubulinTumor MicroenvironmentUp-RegulationConceptsClass III β-tubulinIII β-tubulinClass III β-tubulin expressionNeoadjuvant chemotherapyPoor overall survivalOverall survivalΒ-tubulin expressionClass III β-tubulin overexpressionPrimary cytoreductionNeoadjuvant carboplatin/paclitaxelPoor median overall survivalTumor microenvironmentAdvanced ovarian carcinomaCarboplatin/paclitaxelMedian overall survivalOvarian cancer patientsCell linesCancer stem cellsNeoadjuvant carboplatinPrimary debulkingVitro chemosensitivityClinical outcomesPatient populationCancer patientsStromal expressionClass III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone
Roque DM, Bellone S, Buza N, Romani C, Cocco E, Bignotti E, Ravaggi A, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone. American Journal Of Obstetrics And Gynecology 2013, 209: 62.e1-62.e9. PMID: 23583215, DOI: 10.1016/j.ajog.2013.04.017.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily B, Member 1Cell LineCystadenocarcinoma, SerousDose-Response Relationship, DrugDown-RegulationDrug Resistance, NeoplasmEpothilonesFemaleHumansImmunohistochemistryKaplan-Meier EstimateMicrotubulesNeoplasms, Glandular and EpithelialOvarian NeoplasmsPaclitaxelPrognosisReal-Time Polymerase Chain ReactionTaxoidsTubulinTubulin ModulatorsConceptsClass III β-tubulinClear cell carcinomaIII β-tubulinCell carcinomaOverall survivalP-glycoproteinClass III β-tubulin overexpressionClinical outcomesPolymerase chain reactionPaclitaxel resistanceClass III β-tubulin expressionPlatinum/taxane chemotherapyPoor overall survivalSerous papillary carcinomaChain reactionOvarian clear cellFresh frozen tissue samplesReal-time polymerase chain reactionCell linesTime polymerase chain reactionPolymerase chain reaction resultsΒ-tubulin expressionTaxane chemotherapyPoor outcomePoor prognosisUpdates in therapy for uterine serous carcinoma
Roque DM, Santin AD. Updates in therapy for uterine serous carcinoma. Current Opinion In Obstetrics & Gynecology 2013, 25: 29-37. PMID: 23138439, DOI: 10.1097/gco.0b013e32835af98d.Peer-Reviewed Original ResearchConceptsUterine serous carcinomaSerous carcinomaTreatment of USCPaclitaxel-resistant diseasePI3/Akt/mTOR pathwayClass III β-tubulinEarly-stage diseaseNew target antigensAKT/mTOR pathwayVascular endothelial growth factorDistinct molecular pathogenesisHER2/neuIII β-tubulinCurrent clinical approachesEndothelial growth factorNovel microtubule-stabilizing agentEndometrial cancerAggressive variantOptimal therapyProspective studyPathway aberrationsClinical investigationSmall molecule inhibitorsTarget antigenClinical approach